Abstract
Invasive fungal infections caused by opportunistic fungal pathogens are associated with high mortality rates, mainly due to the occurrence of genotypic and/or phenotypic resistance. One of the causes of phenotypic resistance is the preferred growth of various fungal pathogens as biofilms, which are tolerant or resistant to most classes of antifungal agents. Moreover, increasing evidence points to biofilm formation as a general prerequisite for the development of systemic infections. Therefore, new antibiofilm agents are urgently needed to reduce the incidence of biofilm-associated infections. Nowadays, antimicrobial peptides (AMPs) are considered as valuable alternatives for or complements to the classical antifungal agents to combat fungal infections. Many review reports describe activity of AMPs against free-living planktonic fungal pathogens. In contrast, this review summarizes the antibiofilm properties of natural or synthetic AMPs against fungal biofilms and their potential to enhance the antibiofilm activity of existing antifungal agents.
Keywords: Antimicrobial Peptides, Antifungal, Antibiofilm, Coating, Peptide drugs, Candida spp., Cryptococcus spp.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Antimicrobial Peptides as a Strategy to Combat Fungal Biofilms
Volume: 17 Issue: 5
Author(s): Nicolas Delattin, Katrijn De Brucker, Kaat De Cremer, Bruno P.A. Cammue and Karin Thevissen
Affiliation:
Keywords: Antimicrobial Peptides, Antifungal, Antibiofilm, Coating, Peptide drugs, Candida spp., Cryptococcus spp.
Abstract: Invasive fungal infections caused by opportunistic fungal pathogens are associated with high mortality rates, mainly due to the occurrence of genotypic and/or phenotypic resistance. One of the causes of phenotypic resistance is the preferred growth of various fungal pathogens as biofilms, which are tolerant or resistant to most classes of antifungal agents. Moreover, increasing evidence points to biofilm formation as a general prerequisite for the development of systemic infections. Therefore, new antibiofilm agents are urgently needed to reduce the incidence of biofilm-associated infections. Nowadays, antimicrobial peptides (AMPs) are considered as valuable alternatives for or complements to the classical antifungal agents to combat fungal infections. Many review reports describe activity of AMPs against free-living planktonic fungal pathogens. In contrast, this review summarizes the antibiofilm properties of natural or synthetic AMPs against fungal biofilms and their potential to enhance the antibiofilm activity of existing antifungal agents.
Export Options
About this article
Cite this article as:
Delattin Nicolas, Brucker De Katrijn, Cremer De Kaat, Cammue P.A. Bruno and Thevissen Karin, Antimicrobial Peptides as a Strategy to Combat Fungal Biofilms, Current Topics in Medicinal Chemistry 2017; 17 (5) . https://dx.doi.org/10.2174/1568026616666160713142228
DOI https://dx.doi.org/10.2174/1568026616666160713142228 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells
Current Pharmaceutical Design H19: A Vital Long Noncoding RNA in the Treatment of Diabetes and Diabetic Complications
Current Pharmaceutical Design Chitosan: A Propitious Biopolymer for Drug Delivery
Current Drug Delivery Gene Expression Signatures of Lymph Node Metastasis in Oral Cancer: Molecular Characteristics and Clinical Significances
Current Cancer Therapy Reviews Adenosine A1 Receptors in the Central Nervous System: Their Functions in Health and Disease, and Possible Elucidation by PET Imaging
Current Medicinal Chemistry Glyconanoparticles for Biomedical Applications
Combinatorial Chemistry & High Throughput Screening Curcumin and its Multi-target Function Against Pain and Inflammation: An Update of Pre-clinical Data
Current Drug Targets Pharmacogenomics of Open-Angle Glaucoma
Current Pharmacogenomics and Personalized Medicine Classical to Current Approach for Treatment of Psoriasis: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Thematic Analysis™ : A Chemogenomic Approach to GPCR Drug Discovery
Current Topics in Medicinal Chemistry Commercial Opportunities and Ethical Pitfalls in Personalized Medicine: A Myriad of Reasons to Revisit the Myriad Genetics Saga
Current Pharmacogenomics and Personalized Medicine Antineovascular Agents in the Treatment of Eye Diseases
Current Pharmaceutical Design Construction and Evaluation of Liraglutide Delivery System based on Milk Exosomes: A New Idea for Oral Peptide Delivery
Current Pharmaceutical Biotechnology Potential of Selected Indian Herbs for COVID-19
Current Traditional Medicine Editorial [Hot Topic: Kidney Cancer: State of the Art in 2011 (Guest Editor: Ulka Vaishampayan)]
Current Clinical Pharmacology Targeted Therapy Towards Cancer-A Perspective
Anti-Cancer Agents in Medicinal Chemistry Herbal Phytochemicals as Immunomodulators
Current Immunology Reviews (Discontinued) Apoptosis in the Dentate Nucleus Following Kindling-induced Seizures in Rats
CNS & Neurological Disorders - Drug Targets <i>Drosophila melanogaster</i> a Versatile Model of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Novel Neuroendocrine and Metabolic Mechanism Provides the Patented Platform for Important Rejuvenation Therapies: Targeted Therapy of Telomere Attrition and Lifestyle Changes of Telomerase Activity with the Timing of Neuron-Specific Imidazole-Containing Dipeptide-Dominant Pharmaconutrition Provision
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)